

REMARKS

In response to the office communication dated April 1, 2003, Applicants have amended claims 6, 19, 37, 42, 43, 47, and 61 to use the correct form of sequence identification. Claim 49 has been amended to add a period. The amendments are self-explanatory as to their support. No new matter has been introduced.

Applicants request favorable consideration of the subject application for the following reasons.

1. Figures 1 and 4.

The examiner's communication at page 2 stated that Figures 1 and 4 contained sequences that were not properly identified.

Applicants submit that the specification at page 12, lines 9-19, clearly describes and identifies the contents of Figure 1 including the sequences encompassed therein. In addition, the sequences encompassed in Figure 1 are listed in the Sequence Listing in the subject application. Thus, it is Applicants' understanding that the examiner's communication requests the identification of the sequences in Figure 1 itself, not any corrections to the existing sequence listing or any other part of the specification. Accordingly, Applicants submit herewith under a separate cover sheet a proposed corrected Figure 1 identifying the sequences therein.

Applicants submit that the specification at page 13, lines 8-17, clearly describes and identifies the contents of Figure 4 including the sequences encompassed therein. In addition, the sequences encompassed in Figure 4 are listed in the Sequence Listing in the subject application. Thus, it is Applicants' understanding that the examiner's

communication requests the identification of the sequences in Figure 4 itself, not any corrections to the existing sequence listing or any other part of the specification. Accordingly, Applicants submit herewith under a separate cover sheet a proposed corrected Figure 4 identifying the sequences therein.

2. Figure 11.

The examiner's communication at page 2 stated that Figure 11 contained sequences that were not properly identified.

Applicants submit that the specification at page 14, line 24 to page 14, line 3 and the sequence listings 14-19 clearly describes and identifies the contents of Figure 11 including the sequences encompassed therein. The sequences encompassed in Figure 11 are listed in the Sequence Listing in the subject application having sequence identification numbers 14-19. Thus, it is Applicants' understanding that the examiner's communication requests the identification of the sequences in Figure 11 itself, not any corrections to the existing sequence listing or any other part of the specification. Accordingly, Applicants submit herewith under a separate cover sheet a proposed corrected Figure 11 identifying the sequences therein.

3. Specification including claims 6 and 61.

The examiner's communication requested correction of the specification including claims 6 and 61 to use the proper form of sequence identification throughout the specification.

In response, Applicants submit that the description part of the specification has been amended to use the proper Sequence ID form by the amendment filed on January

23, 2003. Applicants have amended claims 6, 19, 37, 42, 43, 47, and 61 to use the proper Sequence ID form as the examiner's communication requested.


In view of the foregoing, the specification including the figures and claims has been amended in accordance with the USPTO rules and as requested by the Examiner. Applicants note that none of the amendments concern compliance with the sequence rules, 37 C.F.R. §§1.821-1.825. Should the examiner decide that any requirements regarding sequence listing in the subject application are not met, Applicants request that the examiner contact Applicants' attorney and point out more specifically where the correction is needed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

A fee of \$110.00 is due for the extension of time. A check in the same amount is submitted with a separate cover sheet. Should any other fee be required, please charge the same to deposit account number 22-0261 and notify Applicants' attorney.

Respectfully submitted,

Date: June 2, 2003



Ann S. Hobbs (Reg. No. 36,830)
Venable, Baetjer, Howard & Civiletti, LLP
1201 New York Avenue, N.W., Suite 1000
Washington, D.C. 20005
Tel.: (202) 962-4800
Fax: (202) 962-8300

Doc# 460817

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 6, 19, 37, 42, 43, 47, 49, and 61 have been amended as follows:

6. (Amended) The isolated nucleic acid of claim 5 having the sequence given in SEQ ID NO: 1.

19. (Amended) The isolated human synuclein protein or peptide of claim 18 having the sequence given in SEQ ID NO: 5.

37. (Amended) The method of claim 36 wherein said two oligonucleotides have the sequences of SEQ ID NOs ~~NO~~ 2 and SEQ ID NO: 3.

42. (Amended) The oligonucleotide of claim 41 having the sequence of SEQ ID NO: 2.

43. (Amended) The oligonucleotide of claim 41 having the sequence of SEQ ID NO: 3.

47. (Amended) The method of claim 46 wherein said isolated human synuclein protein or peptide has the mutated sequence given in SEQ ID NO: 5.

49. (Amended) The method of claim 48 wherein said mutation is an alanine to threonine substitution.

61. (Amended) The isolated nucleic acid of claim 60 having the sequence given
in SEQ ID NO: 1.